Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bexarotene is a retinoid drug that is approved for the treatment of cutaneous T-cell lymphoma. We report 6 cases in which the initiation of bexarotene therapy for cutaneous T-cell lymphoma was temporally associated with the progression of internal disease despite improvement in cutaneous signs and symptoms. It is possible that bexarotene contributed to this progression. Although bexarotene therapy may alleviate symptoms and signs of cutaneous T-cell lymphoma, careful surveillance of lymph nodes and solid organs during treatment is advised.
Bouwhuis
Saskia A
SA
Departments of Dermatology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Davis
Mark D P
MD
el-Azhary
Rokea A
RA
McEvoy
Marian T
MT
Gibson
Lawrence E
LE
Knudsen
John M
JM
Kist
Joseph M
JM
Pittelkow
Mark R
MR
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077610:Bexarotene; D005260:Female; D006801:Humans; D016399:Lymphoma, T-Cell / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D012751:Sezary Syndrome / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013764:Tetrahydronaphthalenes / Q000009:adverse effects* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene